Chemicals & Advanced Materials Global On demand · 24-48h

Global Cyclodextrin in Pharma Market Strategic Research Report

Global Cyclodextrin in Pharma Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cyclodextrin in Pharma Market
$38.932025
5.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Alpha-Cyclodextrin in Pharma, Beta-Cyclodextrin in Pharma, Gamma-Cyclodextrin in Pharma, CD Derivatives

By Application: Tablets and Capsules, Injectables

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Wacker, Ensuiko Sugar Refining, Nihon Shokuhin Kako, Roquette, Ashland, Shandong Xinda, Yunan Yongguang, Qufu Tianli, Zibo Qianhui, Jiangsu Fengyuan, Mengzhou Huaxing, Mengzhou Hongji

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 106 pages
Market size 2025
$38.93
Million USD
Forecast CAGR
5.8%
2025-2032
Forecast 2032
$57.8
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Cyclodextrin in Pharma market size is predicted to grow from US$ 38.93 million in 2025 to US$ 57.38 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

Cyclodextrins are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by α-1,4 glycosidic bonds. Cyclodextrins are produced from starch by enzymatic conversion. They are used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering.

Global key manufacturers of cyclodextrin in pharma include Wacker, Ensuiko Sugar Refining, Ashland, etc. Global top 3 manufacturers hold a share above 60%. Europe and North America are the major producing regions in the world, followed by China and Japan. In terms of application, the product is most widely used in tablets and capsules, followed by injectables.

The Cyclodextrin industry concentration is relatively high, and high-end products mainly from Japan and Western European. Asia-Pacific is the largest player in the world, the CD is firstly produced in Japan. With the Europe and China players start large production, Japanese domestic production is shrinking.

China is the largest producer now, there are about 50 manufactures in China can product CDs, but only 20+ players put into production now, less than 10 players have the capacity above 1000 MTPA. Most of them are located in Shandong and Jiangsu province.

This report presents a comprehensive overview of the global Cyclodextrin in Pharma market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Alpha-Cyclodextrin in Pharma
  • Beta-Cyclodextrin in Pharma
  • Gamma-Cyclodextrin in Pharma
  • CD Derivatives

Segment by Application

  • Tablets and Capsules
  • Injectables

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cyclodextrin in Pharma market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Tablets and Capsules, Injectables evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cyclodextrin in Pharma Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$38.93
2025
Forecast
$57.8
2032
CAGR
5.8%
2025–2032
Regions
5
global
Key companies
WackerEnsuiko Sugar RefiningNihon Shokuhin KakoRoquetteAshlandShandong XindaYunan YongguangQufu Tianli
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Alpha-Cyclodextrin in PharmaBeta-Cyclodextrin in PharmaGamma-Cyclodextrin in PharmaCD Derivatives
By Application
Tablets and CapsulesInjectables

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Alpha-Cyclodextrin in Pharma
  • 3.1.3 Beta-Cyclodextrin in Pharma
  • 3.1.4 Gamma-Cyclodextrin in Pharma
  • 3.1.5 CD Derivatives
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Tablets and Capsules
  • 4.1.3 Injectables
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Wacker
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Ensuiko Sugar Refining
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Nihon Shokuhin Kako
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Roquette
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ashland
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Shandong Xinda
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Yunan Yongguang
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Qufu Tianli
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Zibo Qianhui
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Jiangsu Fengyuan
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Mengzhou Huaxing
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Mengzhou Hongji
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Cyclodextrin in Pharma market?
The global Cyclodextrin in Pharma market is estimated at US$ 38.93 million in 2025 (base year) and is projected to reach US$ 57.38 million by 2032.
What is the forecast CAGR for the Cyclodextrin in Pharma market?
The market is expected to grow at a CAGR of 5.8% from 2026 to 2032, expanding from US$ 38.93 million in 2025 to US$ 57.38 million in 2032, roughly 1.5 times its base-year value.
What is Cyclodextrin in Pharma?
Cyclodextrins are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by α-1,4 glycosidic bonds. Cyclodextrins are produced from starch by enzymatic conversion. They are used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering.
How is the Cyclodextrin in Pharma market segmented by type?
By type, the market is segmented into Alpha-Cyclodextrin in Pharma, Beta-Cyclodextrin in Pharma, Gamma-Cyclodextrin in Pharma and CD Derivatives.
What are the key applications of Cyclodextrin in Pharma?
Key applications covered include Tablets and Capsules and Injectables.
Which companies are profiled in the Cyclodextrin in Pharma market report?
Key players profiled include Wacker, Ensuiko Sugar Refining, Nihon Shokuhin Kako, Roquette, Ashland, Shandong Xinda, Yunan Yongguang and Qufu Tianli, among 12 companies covered in total.
What geographies does the Cyclodextrin in Pharma market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Cyclodextrin in Pharma market report?
The report is intended for manufacturers and solution providers, distributors and end users in Tablets and Capsules and Injectables, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cyclodextrin in Pharma market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.